Mechanisms of Plaque Formation and Rupture

Author(s): Bentzon JF, Otsuka F, Virmani R, Falk E

Abstract

Atherosclerosis causes clinical disease through luminal narrowing or by precipitating thrombi that obstruct blood flow to the heart (coronary heart disease), brain (ischemic stroke), or lower extremities (peripheral vascular disease). The most common of these manifestations is coronary heart disease, including stable angina pectoris and the acute coronary syndromes. Atherosclerosis is a lipoprotein-driven disease that leads to plaque formation at specific sites of the arterial tree through intimal inflammation, necrosis, fibrosis, and calcification. After decades of indolent progression, such plaques may suddenly cause life-threatening coronary thrombosis presenting as an acute coronary syndrome. Most often, the culprit morphology is plaque rupture with exposure of highly thrombogenic, red cell–rich necrotic core material. The permissive structural requirement for this to occur is an extremely thin fibrous cap, and thus, ruptures occur mainly among lesions defined as thin-cap fibroatheromas. Also common are thrombi forming on lesions without rupture (plaque erosion), most often on pathological intimal thickening or fibroatheromas. However, the mechanisms involved in plaque erosion remain largely unknown, although coronary spasm is suspected. The calcified nodule has been suggested as a rare cause of coronary thrombosis in highly calcified and tortious arteries in older individuals. To characterize the severity and prognosis of plaques, several terms are used. Plaque burden denotes the extent of disease, whereas plaque activity is an ambiguous term, which may refer to one of several processes that characterize progression. Plaque vulnerability describes the short-term risk of precipitating symptomatic thrombosis. In this review, we discuss mechanisms of atherosclerotic plaque initiation and progression; how plaques suddenly precipitate life-threatening thrombi; and the concepts of plaque burden, activity, and vulnerability.

Similar Articles

Global Atlas on Cardiovascular Disease Prevention and Control.

Author(s): Mendis S, Puska P, Norrving B

Pathogenesis of Acute Coronary Syndromes

Author(s): Crea F, Liuzzo G

Matrix Metalloproteinase-9?: Many Shades of Function in Cardiovascular Disease.

Author(s): Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML

Association of serum MMP-9 with autoantibodies against oxidized LDL

Author(s): Kalela A, Koivu TA, Höyhtyä M, Jaakkola O, Lehtimäki T

2013 ESC guidelines on the management of stable coronary artery disease: Eur Heart

Author(s): Montalescot G, Sechtem U, Achenbach S, Andreotti F

Chronic Stable Angina.

Author(s): Abrams J

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.

Author(s): Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A

The oxidation ratio of LDL: a predictor for coronary artery disease.

Author(s): Huang H, Mai W, Liu D, Hao Y, Tao J

Antibodies against oxLDL and acute coronary syndrome.

Author(s): Medeiros AM, von Mühlen CA, Gidlund MA, Bodanese R, Gottlieb MG

Plaque regression and plaque stabilisation in cardiovascular diseases.

Author(s): Dave T, Ezhilan J, Vasnawala H, Somani V

Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease

Author(s): Kalela A, Koivu TA, Sisto T, Kanervisto J, Höyhtyä M